MM-771: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Transplant-ineligible (TIE) Patients in the Phase 3 CEPHEUS Study

Category Primary study
JournalClin. Lymphoma Myeloma Leukemia
Year 2025
This article has no abstract
Epistemonikos ID: 02bb274eef79409162cc0cd31c2f95e15750aea2
First added on: Aug 26, 2025